GlassScriptPhysician profile
Matthew Nissing
NPI 1558324418
$4,830.01
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $343 · 2021: $1,326 · 2022: $1,196 · 2023: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.88 | 2019-2023 | |
| Janssen Biotech, INC. | $1,091.03 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $679.24 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $537.21 | 2019-2023 | Entyvio, Trintellix |
| Nestle Healthcare Nutrition INC. | $312.73 | 2021-2023 | |
| Pfizer INC. | $197.59 | 2019-2023 | |
| Braintree Laboratories, INC. | $117.22 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $116.29 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $102.91 | 2021-2023 | Linzess |
| Qol Medical, LLC | $81.70 | 2022-2023 | Sucraid |
| Amgen INC. | $75.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $73.92 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $72.06 | 2019-2022 | |
| Ucb, INC. | $55.71 | 2019-2020 | |
| Celgene Corporation | $48.17 | 2021-2023 | Zeposia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $37.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.83 | 2019-2023 | Cyltezo |
| Ardelyx, INC. | $31.04 | 2022-2023 | Ibsrela |
| Fresenius Kabi USA, LLC | $18.73 | 2023 | Idacio |
| Esperion Therapeutics, INC. | $16.01 | 2021 | |
| Mylan Institutional INC. | $15.37 | 2023 | Hulio |
| Redhill Biopharma INC. | $15.30 | 2022 | |
| Glaxosmithkline, LLC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nissing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.